article
3 October 2014 | By Andrew G. Popplewell (UCB Pharma), Daniel Lightwood (UCB Pharma), Gillian M. Burgess (UCB Pharma)
The use of monoclonal antibodies and antibody-based molecules as therapeutics to treat patients suffering with severe disease has become a major success story. Due to the exquisite specificity with which they interact with their antigen and the fact that their large binding surface can intervene at sites and targets not…